Clinically high expression of NOD1 was linked to shorter over survival (OS), relapse-free survival (RFS), and distant metastasis-free survival (DMFS) of breast cancer patients who received neoadjuvant chemotherapy (Fig. 2J). The gene discussed is NOD1; the disease is breast carcinoma.